Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Protalix BioTherapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue Revenues from selling goods of $5.1 million and revenues from license and R&D services of $4.5 million, net income Net loss of approximately $3.1 million, EPS loss of $0.05 per share.
- Period
- first quarter ended March 31, 2023
- Revenue
- Revenues from selling goods of $5.1 million and revenues from license and R&D services of $4.5 million
- Net income
- Net loss of approximately $3.1 million
- EPS
- loss of $0.05 per share
- Result
- reported results
Exact text from the filing
First Quarter 2023 Financial Highlights ● The Company recorded revenues from selling goods of $5.1 million during the three months ended March 31, 2023, a decrease of $3.9 million, or 43%, compared to revenues of $9.0 million for the three months ended March 31, 2022. The decrease resulted primarily from a decrease of $2.7 million in sales to Brazil and a decrease of $1.1 million in sales to Pfizer, both resulting from timing differences. ● The Company recorded revenues from license and R&D services of $4.5 million for the three months ended March 31, 2023, a decrease of $2.6 million, or 37%, compared to revenues of $7.1 million for the three months ended March 31, 2022. Revenues from license and R&D services are comprised primarily of revenues the Company recognized in connection with the Chiesi Agreements. ● Cost of goods sold was $3.1 million for the three months ended March 31, 2023, a decrease of $2.9 million, or 48%, from cost of goods sold of $6.0 million for the three months en
View on SEC.gov